Current insights into the modern treatment of decompensated heart failure;Tratamento atual da insuficiência cardíaca descompensada

Arquivos Brasileiros de Cardiologia

Volumn 87, Issue 3, 2006, Pages

  Vilas Boas, Fábio ^a   Follath, Ferenc ^b  

^a Hospital Espanhol   (Brazil)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Acute; Decompensated; Heart failure; Treatment

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM SENSITIZER; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; GLYCERYL TRINITRATE; HYPERTENSIVE FACTOR; INOTROPIC AGENT; LEVOSIMENDAN; MILRINONE; NESIRITIDE; NITROPRUSSIDE SODIUM; NORADRENALIN; VASODILATOR AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CARDIOTONIC AGENT;

ACUTE HEART FAILURE; CARDIOGENIC SHOCK; CLINICAL TRIAL; DIET; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; EXERCISE; HEART ATRIUM ARRHYTHMIA; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HEMODYNAMICS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERTENSION; INCIDENCE; LENGTH OF STAY; LUNG EDEMA; REVIEW; SURVIVAL RATE; TACHYCARDIA; TISSUE OXYGENATION; UNITED STATES; ALGORITHM; CONGESTIVE HEART FAILURE; DRUG COMBINATION;

ADRENERGIC ALPHA-AGONISTS; ALGORITHMS; CARDIOTONIC AGENTS; DIURETICS; DRUG THERAPY, COMBINATION; HEART FAILURE, CONGESTIVE; HUMANS; VASODILATOR AGENTS;

EID: 33750310816     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Cleland JG, Gemmell I, Khand A, Boddy A. Is the prognosis of heart failure improving? Eur J Heart Fail 1999; 1: 229-41.
2. Barker WH, Mullooly JP, Getchell W. Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990-1994. Circulation. 2006;113(6):799-805.
3. Bocchi EA, Vilas-Boas F, Perrone S, et al. I Latin American Guidelines for the Assessment and Management of Decompensated Heart Failure. Arq Bras Cardiol. 2005;85 Suppl 3:49-94; 1-48.
4. Sarmento PM, Fonseca C, Marques F, Ceia F, Aleixo A. Acutely decompensated heart failure: characteristics of hospitalized patients and opportunities to improve their care. Rev Port Cardiol. 2006;25(1):13-27.
5. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26(11):1115-40.
6. Revisão das II Diretrizes da Sociedade Brasileira de Cardiologia para o Diagnóstico e Tratamento da Insuficiência Cardíaca. Arq Bras Cardiol. 2002;79 (supl IV): 1-30.
7. Hunt AS, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46(6):e1-82.
8. Nieminen MS, Bohm M, Cowie MR, et al. ESC Committee for Practice Guideline (CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26(4):384-416.
9. Jaagosild P, Dawson NV, Thomas C, et al. Outcomes of acute exacerbation of severe congestive heart failure: quality of life, resource use, and survival. Arch Intern Med 1998; 158: 1081-89.
10. Pang D, Keenan SP, Cook DJ, et al. The effect of positive pressure airway support on mortality and the need for intubation in cardiogenic pulmonary edema: a systematic review. Chest 1998;114:1185-1192.
11. Stevenson LW, Colucci WS. Management of patients hospitalized with heart failure. In: Smith TW, ed. Cardiovascular Therapeutics. Philadelphia, Penna: Saunders; 1996:199-209.
12. Piepoli MF, Davos C, Francis DP, Coats AJ. ExTraMATCH Collaborative. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH).. BMJ. 2004;328(7433):189.
13. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
14. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
15. Pflugfelder PW, Baird MG, Tonkon MJ, DiBianco R, Pitt B, for the Quinapril Heart Failure Trial Investigators. Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. J Am Coll Cardiol 1993;22:1557-63.
16. Massie BM, Armstrong PW, Cleland JG, et al. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial: the Assessment of Treatment with Lisinopril and Survival. Arch Intern Med 2001;161:165-71.
17. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
18. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362:767-71.
19. Pitt B, Zannad F, Remme WJ, et al, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
20. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321
21. Packer M, Bristow MR, Cohn JN, et al, for the U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
22. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90.
23. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
24. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial. Lancet 2003;362:7-13.
25. Gattis WA, O'Connor CM, Leimberger JD, Felker GM, Adams KF, Gheorghiade M. Clinical. Outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. Am J Cardiol. 2003;91(2):169-74.
26. Bristow MR, Shakar SF, Linseman JV, Lowes BD. Inotropes and beta-blockers: is there a need for new guidelines? J Card Fail 2001;7(2 Suppl 1):8-12.
27. Metra M, Nodari S, D'Aloia A, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 2002;40:1248-1258.
28. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-534.
29. Dormans TP, van Meyel JJ, Gerlag PG, Tan Y, Russel FG, Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 1996;28:376-82.
30. Ellison DH. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann Intern Med 1991;114:886-94.
31. Kishore J, Harjai MBBS, Homeyar K et al. The prognostic implications of outpatient diuretic dose in heart failure. Int J Cardiol 1999;71:219-25.
32. Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999;100(12):1311-5.
33. Steimle AE, Stevenson LW, Chelinsky-Fallick C, et al. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation 1997; 96:1165-72.
34. Rohde LE, Furian T, Campos C, Biolo A, Rabelo E, Foppa M, Clausell N. Implications of the hemodynamic optimization approach guided by right heart catheterization in patients with severe heart failure. Arq Bras Cardiol. 2002;78(3):261-6.
35. Chernow B. Pulmonary artery flotation catheters: A statement by the American College of Chest Physicians and the American Thoracic Society. Chest 1997;111:261.
36. Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005;294(13):1625-33.
37. Jugdutt BI. Intravenous nitroglycerin unloading in acute myocardial infarction. Am J Cardiol. 1991;68(14):52D-63D.
38. Abrams J. How to use nitrates. Cardiovasc Drugs Ther. 2002;16(6):511-4.
39. Mills RM. The failing heart and the hemodynamic response to vasodilator therapy.Clin Cardiol. 2003;26(6):257-8.
40. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996;94:3184-9.
41. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343:246-53.
42. Silver MA, Horton DP, Ghali JK, Elkayam U. Effect of Nesiritide Versus Dobutamine on Short-Term Outcomes in the Treatment of Patients With Acutely Decompensated Heart Failure . J Am Coll Cardiol 2002;39:798-803.
43. The VMAC investigators. Intravenous nesiritide vs nitroglycerin for the treatment of decompensated congestive heart failure. JAMA 2002;287:1531-1540.
44. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487-1491.
45. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term Risk of Death After Treatment With Nesiritide for Decompensated Heart Failure. A Pooled Analysis of Randomized Controlled Trials. JAMA. 2005;293:1900-1905.
46. Scios. Scios announces international outcomes trial of NATRECOR® (nesiritide) [press release]. June 1, 2006. Available at: http://www.sciosinc. com/scios/pr_1149131419
47. Francis GS, Sharma B, Hodges M. Comparative hemodynamic effects of dopamine and dobutamine in patients with acute cardiogenic circulatory collapse. Am Heart J. 1982;103(6):995-1000.
48. Van De Borne P, Somers VK. Dopamine and congestive heart failure: pharmacology, clinical use, and precautions. Congest Heart Fail. 1999;5(5):216-221.
49. Kellum JA, M Decker J. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med. 2001;29(8):1526-31.
50. Schreiber W, Herkner H, Koreny M, et al. Predictors of survival in unselected patients with acute myocardial infarction requiring continuous catecholamine support. Resuscitation. 2002;55(3):269-76.
51. Leier CV, Binkley PF. Parenteral inotropic support for advanced congestive heart failure. Prog Cardiovasc Dis. 1998;41:207-224.
52. Ander DS, Jaggi M, Rivers E, et al. Undetected cardiogenic shock in patients with congestive heart failure presenting to the emergency department. Am J Cardiol. 1998;82(7):888-91.
53. Holubarsch C. New inotropic concepts: rationale for and differences between calcium sensitizers and phosphodiesterase inhibitors. Cardiology 1997;88 (suppl 2):12-20.
54. Dies F, Krell MJ, Whitlow P, et al. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure. Circulation 1986;74: II-38.
55. Hampton JR, van Veldhuisen DJ, Kleber FX, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe failure: Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II). Lancet 1997; 349: 971-77.
56. Packer M. The search for the ideal positive inotropic agent. N Engl J Med. 1993;329:201-202.
57. Connors AFJ, Speroff T, Dawson NV, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. JAMA 1996; 276:889-97.
58. Hayes MA, Timmins AC, Yau EHS, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994;330:1717-22.
59. Capomolla S, Febo O, Opasich C, et al. Chronic infusion of dobutamine and nitroprusside in patients with end-stage heart failure awaiting heart transplantation: safety and clinical outcome. Eur J Heart Fail 2001;3(5):601-10.
60. Thackray S, Eastaugh J, Freemantle N, Cleland JGF. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure: a meta-regression analysis. Eur J Heart Fail 2002;4(4):515-29.
61. Cuffe MS, Califf RM, Adams KF, et al. Short term intravenous milrinone for acute exacerbation of chronic heart failure. A randomized controlled trial. JAMA 2002;287:1541-47.
62. Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study.J Am Coll Cardiol. 2003;41:997-1003.
63. Lowes BD, Tsvetkova T, Eichhorn EJ, Gilbert EM, Bristow MR. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol. 2001;81(2-3):141-9.
64. Figgit D, Gillies PS, Goa KL. Levosimendan. Drugs 2001;61(5):613-627.
65. Hasenfuss G, Pieske B, Kretschmann B, Holubarsch C, Alpert NR, Just H. Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics. J Cardiovasc Pharmacol 1995; 26 (suppl 1):S45-51.
66. Michaels AD, McKeown B, Kostal M, et al Effects of Intravenous Levosimendan on Human Coronary Vasomotor Regulation, Left Ventricular Wall Stress, and Myocardial Oxygen Uptake. Circulation. 2005;111:1504-1509.
67. Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000;102:2222-27.
68. Follath F, Cleland JGF, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
69. Nieminen MS, Moiseyev VS, Andrejevs N, et al. Randomized study on safety and effectiveness of levosimendan in patients with left ventricular failure after an acute myocardial infarction (RUSSLAN). European Heart Journal 2002;23:1422-32.
70. Lehmann A, Lang J, Boldt J, Isgro F, Kiessling AH. Levosimendan in patients with cardiogenic shock undergoing surgical revascularization: a case series. Med Sci Monit. 2004;10(8):MT89-93.
71. Packer M. REVIVE II: Multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure. Program and abstracts from the American Heart Association Scientific Sessions 2005; November 13-16, 2005; Dallas, Texas. Late Breaking Clinical Trials II.
72. Mebazaa A. The SURVIVE Trial: Comparison of dobutamine and levosimendan on survival in acute decompensated heart failure. Program and abstracts from the American Heart Association Scientific Sessions 2005; November 13-16, 2005; Dallas, Texas. Late Breaking Clinical Trials IV.
73. Nanas JN, Papazoglou PP, Terrovitis JV, et al. Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone. Am J Cardiol. 2004;94(10):1329-32.
74. Cleland JGF, Takala A, Apajasalo M, Zethraeus N, Kobelt G. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial. Eur J Heart Fail 2003;5;101-108.
75. Oliveira MT Jr, Follador W, Martins ML, et al. Cost analysis of the treatment of acute decompensated heart failure : Levosimendan versus Dobutamine. Arq Bras Cardiol. 2005;85(1):9-14.